Table 1.
Characteristic | CF (n = 3) | HC (n = 4) |
---|---|---|
Sex, female % (n) | 33% (1) | 50% (2) |
Average age, years (SD) | 28 ± 4.6 | 29 ± 6.1 |
FEV1, per cent predicted (SD) | 89.8 ± 11 | |
Pa colonization % (n) | 67% (2) | |
Staph aureus colonization % (n) | 33% (1) | |
F508del/F508del % (n) | 100% (3) | |
CFTR modulator use (within 12 mo) % (n) | 0% (0) | |
Dornase alpha use % (n) | 100% (3) | |
Hypertonic saline use % (n) | 67% (2) | |
Azithromycin use % (n) | 67% (2) | |
Inhaled antibiotic use % (n) | 0% (0) | |
Oral/IV antibiotics within 6 mo % (n) | 0% (0) | |
Pancreatic insufficiency % (n) | 100% (3) | |
CFRD % (n) | 0% (0) | |
CF liver disease | 0% (0) |